We treated 79 patients with a neoplastic pathology of the testicle between 1972 and 1993. The average age of patients was 35 (range 17-75). Seminoma were treated with precautional and/or therapeutic cycles of TCT. In the 14 cases (38.8%) of non-seminomatous germ cell tumours (NSGCT) there was a difference between the clinical and the pathological staging after retroperitoneal lymph-node dissection (RPLND). Mortality due to progression of the disease was 3.8%. The 17 patients (47.2%) who underwent RPLND had an andrological follow-up (10 patients with normal ejaculation and 7 with no ejaculation). We confirm the under-staging of preliminary diagnostic investigations. Unlike some authors, we feel that conservative action (orchiectomy alone), is not sufficient even in first stage NSGCT.

Background: Cancer pain evolve and change with disease progression. It has both a nociceptive and neuropathic component.Among strong analgesics, which still represent the cornerstone of management in cancer patients with moderate-to-severe chronic pain, tapentadol is a unique chemical entity. Due to its mechanism, we decided to evaluate efficacy and tolerability of tapentadol, a dual -opioid and noradrenergic (MOR-NRI) -central acting analgesic with effectiveness in chronic and mixed pain. The lower contribution of the opioid component also allows a reduction in adverse events μ-related. Moreover Tapentadol has a low risk of drug interactions which can be very useful in patients with complex therapeutic programmes.